Status:
COMPLETED
Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Emergent Product Development Seattle LLC
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.
Eligibility Criteria
Inclusion
- Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit.
- Must meet criteria for rheumatoid arthritis with functional class I to III.
- Diagnosis of rheumatoid arthritis more than 6 months before study day 1 and rheumatoid arthritis onset after 16 years of age
Exclusion
- Any significant health problems other than rheumatoid arthritis.
- Treatment of greater than 10 mg of prednisone per day.
- Treatment with cyclophosphamide.
Key Trial Info
Start Date :
March 31 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00641225
Start Date
March 31 2008
End Date
March 31 2011
Last Update
September 13 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Miami, Florida, United States, 33143
2
Pfizer Investigational Site
Durham, North Carolina, United States, 27710
3
Pfizer Investigational Site
Dallas, Texas, United States, 75231
4
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 2B7